Mirum Pharmaceuticals, Inc.
MIRMDrugs in Pipeline
13
Phase 3 Programs
8
Upcoming Catalysts
5
Next Catalyst
This month
Market Overview
Stock performance and key metrics
5 upcoming, 1 past
Brelovitug 300 mg Phase 3 Est. Readout
Primary completion for Brelovitug 300 mg trial (NCT07298330) in Chronic Hepatitis D Infection
Source4 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How MIRM's past catalysts played out
Blinded CDCA 250 mg TID
CTX
Brelovitug 900 mg
Chronic Hepatitis D Infection
Brelovitug 300 mg
Chronic Hepatitis D Infection
Bulevirtide 2 mg and Brelovitug - 300 mg
Chronic Hepatitis D Infection
Brelovitug (BJT-778)
Chronic Hepatitis D
Maralixibat
Biliary Atresia
Cholic acid
Inborn Errors of Bile Acid Synthesis
Cholic Acids
Infantile Refsum's Disease
Low dose of MRM-3379
Fragile X Syndrome
LUM001 (Maralixibat)
Alagille Syndrome
Ursodeoxycholic Acid
PBC
Volixibat
Primary Biliary Cholangitis
LUM001
Alagille Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Blinded CDCA 250 mg TID | Phase 3 | CTX | - | - |
Brelovitug 900 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Brelovitug 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Bulevirtide 2 mg and Brelovitug - 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D | - | - |
Maralixibat | Phase 3 | Biliary Atresia | - | - |
Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis | - | - |
Cholic Acids | Phase 3 | Infantile Refsum's Disease | - | - |
Low dose of MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome | - | - |
Ursodeoxycholic Acid | Phase 2 | PBC | - | - |
Volixibat | Phase 2 | Primary Biliary Cholangitis | - | - |
LUM001 | Phase 2 | Alagille Syndrome | - | - |
Alagille Syndrome
3 drugs in this indication
Inborn Errors of Bile Acid Synthesis
1 drug in this indication
PBC
1 drug in this indication
Fragile X Syndrome
1 drug in this indication
Biliary Atresia
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
CTX
1 drug in this indication
Infantile Refsum's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mirum Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in Mirum Pharmaceuticals, Inc.'s (MIRM) pipeline across Phase 3, Phase 2. Its lead program is Blinded CDCA 250 mg TID (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mirum Pharmaceuticals, Inc.'s next FDA catalyst?→
Mirum Pharmaceuticals, Inc.'s (MIRM) next tracked catalyst is a Phase 3 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MIRM biotech catalysts?→
Add MIRM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mirum Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.